Ligand Pharmaceuticals Reports Strong Q4 & Full Year 2025 Results, Exceeding EPS Guidance by 30% and Reaffirming 2026 Outlook
LGND has more than doubled off its 52-week low of $93.58.
Summary
Ligand Pharmaceuticals announced robust fourth quarter and full year 2025 financial results, significantly exceeding its initial full-year adjusted EPS guidance by approximately 30%, driven by strong royalty revenue growth and positive pipeline advancements. The company also reaffirmed its 2026 financial guidance.
Key Events · Earnings and Guidance · LGND
-
Strong Financial Performance
Reported Q4 2025 total revenues of $59.7 million (+39% YoY) and full year 2025 total revenues of $268.1 million (+60% YoY).
-
Significant EPS Beat
Full year 2025 adjusted EPS of $8.13 exceeded initial guidance by approximately 30%, a substantial improvement from a GAAP net loss in 2024.
-
Robust Royalty Revenue Growth
Full year 2025 royalty revenue grew 48% to $161.0 million, driven by increased sales of key products like Filspari, Capvaxive, and Ohtuvayre.
-
2026 Guidance Reaffirmed
The company reiterated its 2026 financial guidance, projecting total revenues of $245-$285 million and adjusted EPS of $8.00-$9.00, demonstrating confidence in future performance.
Analysis · LGND · Life Sciences
This 8-K reports highly positive financial performance for Ligand Pharmaceuticals, with the company achieving a substantial turnaround from a GAAP net loss in 2024 to significant profitability in 2025. The reported full-year 2025 adjusted EPS of $8.13 notably surpassed initial guidance by approximately 30%, indicating strong operational execution and better-than-expected performance across its royalty portfolio. The reaffirmation of 2026 financial guidance, including projected revenues of $245-$285 million and adjusted EPS of $8.00-$9.00, signals management's confidence in sustained growth. Additionally, the filing highlights multiple positive developments in key partnered programs, such as a successful Phase 3 trial for Qtorin rapamycin and expedited FDA review for Tzield, further strengthening the company's long-term value proposition.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 36.1% of the 1758 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.05%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LGND was trading at $191.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $93.58 to $212.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.